Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brimonidine topical gel - Galderma

Next Previous
Drug Profile

Brimonidine topical gel - Galderma

Alternative Names: Brimonidine tartrate gel; CD 07805/47; COL 118; Col-118; Mirvaso; Onreltea; Sansrosa; SR-101

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SansRosa Pharmaceutical Development
  • Developer Galderma
  • Class Antiglaucomas; Antihypertensives; Bromobenzenes; Diamines; Eye disorder therapies; Imidazoles; Quinoxalines; Skin disorder therapies; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Erythema

Most Recent Events

  • 03 Jun 2020 Launched for Erythema in Russia (Topical) before June 2020
  • 09 Aug 2019 No development reported - Phase-II for Erythema (Prevention) in Germany (Topical)
  • 09 Aug 2019 No development reported - Phase-III for Erythema in Russia (Topical)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top